Market revenue in 2023 | USD 53.4 million |
Market revenue in 2030 | USD 115.3 million |
Growth rate | 11.6% (CAGR from 2023 to 2030) |
Largest segment | Immunotherapy |
Fastest growing segment | Immunotherapy |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Chemotherapy, Immunotherapy, Targeted Therapy |
Key market players worldwide | Eli Lilly and Co, Sanofi SA, Merck & Co Inc, Bristol-Myers Squibb Co, AstraZeneca PLC, Takeda Pharmaceutical Co Ltd, Teva Pharmaceutical Industries Ltd, Roche Holding AG ADR, Clinigen Group |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to head and neck cancer therapeutics market will help companies and investors design strategic landscapes.
Immunotherapy was the largest segment with a revenue share of 60.11% in 2023. Horizon Databook has segmented the Spain head and neck cancer therapeutics market based on chemotherapy, immunotherapy, targeted therapy covering the revenue growth of each sub-segment from 2018 to 2030.
Spain’s pharmaceutical sector has continued to receive major investments, which is anticipated to influence the head and neck cancer therapeutics drugs market positively. The country has a high prevalence of head and neck cancer, which further results in market growth.
The country’s supportive healthcare policies & initiatives to increase public awareness and monitor head and neck cancer are expected to increase the demand for head and neck cancer therapeutics in the country.
In September 2023, researchers at Vall d'Hebron Institute of Oncology (VHIO), a Spain-based institute, participated in a study that demonstrated the use of pembrolizumab in head and neck cancer treatment. Such involvements in research and development offer growth opportunities for developing head and neck cancer therapeutics in Spain.
Horizon Databook provides a detailed overview of country-level data and insights on the Spain head and neck cancer therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into Spain head and neck cancer therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account